What's in Marinus Pharmaceuticals's pipeline?

Marinus Pharmaceuticals has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Marinus Pharmaceuticals's portfolio?

Top competitors by shared drug class: Biogen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/marinus.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Marinus Pharmaceuticals — Portfolio Competitive Intelligence Brief

Marinus Pharmaceuticals (MRNS) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

MRNS (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ztalmy	GANAXOLONE	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-2/beta-1/gamma-2	Neuroscience	2022-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biogen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Marinus Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Marinus Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/marinus. Accessed 2026-05-14.